An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation

Rationale Initial screening of new medications for potential efficacy (i.e., Food and Drug Administration (FDA) early phase 2), such as in aiding smoking cessation, should be efficient in identifying which drugs do, or do not, warrant more extensive (and expensive) clinical testing. Objectives This...

Ausführliche Beschreibung